drugset / Trial / NCT00085956

Effects of Arzoxifene on Bone Mass and the Uterus

NCT00085956

Phase 3 Completed 300 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindPrevention

Summary

The purposes of this study are to determine: * The effects of arzoxifene on bone mineral density (bone mass) at the spine and hip in postmenopausal women. * The effects of arzoxifene on the uterus (womb) in postmenopausal women. * The effects of arzoxifene on blood tests that measure changes in bone rebuilding in postmenopausal women with low bone density. * The effects of arzoxifene on blood lipids (fats) and other blood markers of heart disease risk. * The safety of arzoxifene and any side effects that might be associated with its use.

Timeline

Start
2004-04
Primary completion
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject arzoxifene Other / unclassified